![BeardBros_BlogImages [Recovered]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjU2MCAyOTIiIHdpZHRoPSIyNTYwIiBoZWlnaHQ9IjI5MiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj48L3N2Zz4=)
Key Takeaways
- France’s Minister of Health confirmed that the long-awaited France medical cannabis regulations will be published in July 2026.
- Despite the publication, patient access to cannabis will likely not begin until early 2027 due to several administrative hurdles.
- The U.CANNABIS study showed significant reductions in opioid use among patients, fueling the push for regulatory progress.
- Major obstacles include a lack of trained prescribers and uncertainty around reimbursement by French social security.
- France aims to learn from Germany and the UK to avoid pitfalls and effectively roll out its medical cannabis market.
EUROPE, FRANCE – France’s Minister of Health confirmed to Agence France-Presse (AFP), that long-delayed regulatory texts for a generalized medical cannabis market will be published upcoming in July. After five years of pilot limbo, France is on the verge of opening one of Europe’s largest potential medical cannabis markets. But prescriber shortages, unresolved reimbursement questions, and strict product rules mean real patient access is still likely years away. Germany and the UK offer a useful before-and-after comparison of what happens when countries get this right, and what happens when they don’t.
France has been sitting on its medical cannabis regulatory texts for two years. That wait, according to the country’s health minister, is almost over.
So What’s New?
In a statement to Agence France-Presse, France’s Minister of Health confirmed that the regulatory texts necessary to launch the country’s generalized medical cannabis market will be published in July 2026. The announcement followed a forced release of data from the U.CANNABIS study. France’s own official scientific evaluation of its medical cannabis pilot, which showed meaningful reductions in opioid and analgesic use among patients enrolled in the program.
The data had sat unpublished since September 2025 before a formal request by cannabis industry association UIVEC (l’Union des industriels pour la valorisation des extraits de chanvre) compelled French authorities to release it.
Ludovic Rachou, President of UIVEC, put it plainly: “The scientific data is stacking up and converging. It is French, it is public, it is solid. We are asking the government to publish the texts before the end of June 2026. Patients in therapeutic impasse have waited long enough.”
July’s publication will mark the beginning of a final regulatory process. It won’t mark the beginning of generalized prescribing. The distinction matters enormously, and understanding it requires a clear picture of where France has been, where Germany has gone, and why the UK serves as a cautionary tale no one wants to repeat.
Why Has France’s Medical Cannabis Market Taken So Long to Launch?
France launched its medical cannabis pilot program in March 2021. The program was designed as a two-year proof of concept, a controlled experiment that would build the evidence base needed to justify a permanent, generalized national framework.
Five years later, that framework still doesn’t exist.
Political instability was the primary obstacle. Without a functioning legislative majority for much of 2023 and 2024, regulatory texts that needed ministerial sign-off collected dust. Patient numbers inside the pilot reflected the dysfunction directly: enrollment peaked at around 3,000 patients and then fell to approximately 700 as clinical uncertainty, administrative delays, and restricted prescriber access drove people away from the program.
The 2024 Social Security Finance Act changed the legal picture. That legislation made generalization a binding legal obligation, not a policy option. By early 2026, with a more stable government in place, the final regulatory steps were finally moving forward. Draft decree texts had been notified to the European Commission in March 2025, opening a three-month observation window for member states to raise objections. None were raised.
As of this June, the key decree, which sets out how cannabis-based medicines will be evaluated and priced under France’s social security framework remains unpublished. Until it is, the Haute Autorité de Santé (HAS) cannot issue a formal reimbursement opinion. Without that opinion, companies cannot register products with ANSM, France’s medicines regulator. Without product registration, generalized prescribing cannot begin.
July’s announcement starts that chain reaction. It does not complete it.
What Does The U.CANNABIS Study Actually Show?
The U.CANNABIS study was commissioned directly by ANSM and conducted independently by Inserm UMR 1219 and the AHeaD epidemiology team at the Université de Bordeaux. Researchers tracked healthcare consumption data for 1,971 patients across five approved indications in the twelve months before and six months after they began medical cannabis treatment. Importantly, the outcomes were not self-reported, they were drawn from actual reimbursement records in the SNDS, France’s national social security database.
The headline finding: medical cannabis initiation showed “a positive impact, albeit of low intensity, on healthcare use.” The results were statistically significant across most indications, with modest effect sizes.
The strongest signal came from refractory neuropathic pain, which accounted for 1,105 of the enrolled patients. After initiating medical cannabis treatment:
- The share of patients receiving analgesics fell from approximately 73% to 69%
- Gabapentinoid use dropped by around 3 per 100 patients
- Strong opioid use declined by 1.4 per 100 patients
- Benzodiazepine use fell by 1.6 per 100 patients
- Monthly specialist chronic pain clinic attendances dropped by approximately 0.9 per 100 patients per month
In palliative care, the reductions were larger in absolute terms: approximately 21 in every 100 patients were no longer on strong opioids after treatment began, and average daily opioid doses declined by 13.6 defined daily doses per patient.
In oncology, approximately 12 in 100 fewer patients received analgesics post-initiation. ANSM pharmacovigilance monitoring recorded zero cases of addiction or misuse across the full experimentation — a safety record that will weigh heavily in the reimbursement debate.
For HAS, which must determine whether cannabis-based medicines are displacing existing treatments or simply supplementing them, the SNDS methodology is exactly the kind of evidence the reimbursement evaluation process is designed to weigh.
What Are the Biggest Obstacles to Patient Access in France After July?
Even with the regulatory texts published in July, France faces three structural barriers that could limit how quickly, and how much patients can actually access medical cannabis.
Will There Be Enough Trained Prescribers to Meet Demand?
This is the most immediate constraint. France currently has 2,291 trained healthcare professionals eligible to participate in the medical cannabis system: 531 specialist doctors, 213 general practitioners, and 1,471 pharmacists (472 hospital-based, 999 retail), according to the Augur Associates State of the Medical Cannabis Industry in France 2025 report.
The government’s own projections estimate 5,454 patients in 2026. Prohibition Partners projects that number could reach 457,129 by 2035. The math is stark: if patient volumes scale toward those mid-decade projections without a corresponding expansion in trained prescribers, each eligible professional would need to manage hundreds of patients simultaneously.
The permanent framework expands the prescriber base beyond hospital specialists — general practitioners will be able to renew treatment cycles — but mandatory training certification remains a prerequisite. Unless the training pathway is simplified and scaled, generalization will open a market that structurally cannot serve the demand it generates.
How Much Will the State Reimburse?
Reimbursement is the single most consequential variable in France’s medical cannabis market. The French healthcare system’s social security model means patients generally expect substantial state coverage. Preliminary analysis cited in the Augur report illustrates the stakes clearly:
- No reimbursement: niche, out-of-pocket market; roughly 5,000–10,000 accessible patients
- 30% reimbursement: moderate accessibility; 50,000+ patients potentially reachable
- 65% reimbursement: mainstream medical adoption; 100,000+ patients within 24 months of launch
Prohibition Partners projects the French market could grow from approximately €9.6 million in 2026 to €806 million by 2035 — but only under conditions where reimbursement structures actually support access. The HAS reimbursement opinion, expected in autumn 2026 at the earliest, will determine which of those scenarios is closest to reality.
What Products Are Actually Allowed in France?
France is culturally and politically opposed to combustion. The compromise that emerged from the pilot — and which the permanent framework is expected to continue — is unusual by European standards: flower will be permitted, but only in sealed capsules designed for vaporization using approved medical devices.
During the pilot, the Mighty Medic vaporization device, manufactured by Storz & Bickel (owned by Canopy Growth), was the approved standard. Pharmacists provided mandatory patient training using demonstration kits. That model is expected to continue under the permanent framework.
What this means practically is that France is not building a flower market in the way Germany has. Loose dried flower is explicitly excluded. Producers must align their products with specific monographs for vaporization, and those products must be compatible with approved medical devices. The supply chain demands are pharmaceutical-grade, and the competitive advantage will sit with vertically integrated companies that can meet both the product and device requirements simultaneously.
Domestic cultivators are still progressing through GMP certification and are unlikely to supply national demand before 2028. A two-to-three-year import reliance window is the near-term reality.
How Does France’s Approach Compare to Germany’s Medical Cannabis Market?
Germany is the benchmark every European market gets measured against, and for good reason.
Germany’s MedCanG Act took effect on April 1, 2024, removing cannabis from the country’s narcotics list and classifying it as a standard prescription medicine. That single change eliminated most of the administrative friction that had constrained access under the previous framework. Any licensed physician in Germany can now prescribe medical cannabis. Telemedicine platforms — over 30 of which are now operating in the German market — made access faster and wider, with the five largest providers collectively logging over 200,000 monthly visits.
The numbers that followed were significant. Medical cannabis imports doubled between 2023 and 2024, rising from 31,613 kilograms to 72,122 kilograms. By the first three quarters of 2025, Germany had already imported 142,309 kilograms. Patient numbers jumped from approximately 250,000 in April 2024 to an estimated 900,000 by the end of that year, according to Grand View Research. Prohibition Partners estimates Germany’s 2025 medical cannabis market size in the range of €636 million to €1.34 billion, depending on dispensed volumes and price levels.
What Can France Learn From Germany’s Market?
Germany’s lesson for France is not that France should copy Germany’s model — France has made clear it won’t. The lesson is about timing. Companies that built distribution infrastructure and pharmacy relationships in Germany before the MedCanG took effect captured dominant positions quickly. Tilray, which acquired pharmaceutical distributor CC Pharma in 2019, holds approximately 20% of Germany’s medical cannabis market today. Aurora Cannabis secured one of only three domestic cultivation licenses. The early movers won.
That window is opening now in France. The regulatory texts haven’t even been published yet, and the companies positioning for pharmacy distribution partnerships, device certifications, and GMP import volumes are already in motion.
One caveat: Germany’s trajectory is not guaranteed to continue uninterrupted. A new CDU/CSU-led government has proposed restrictions on telemedicine and mail-order pharmacies, citing concerns about minor access and digital commerce. The Federal Cabinet approved a draft bill in October 2025, which had its first Bundestag reading in December 2025, with further votes expected in spring 2026. Depending on what survives the legislative process, Germany’s growth curve could flatten.
How Does France’s Patient Access Situation Compare to the UK’s?
The UK is a harder story. Cannabis was made legal for medical use in the United Kingdom in 2018, nearly three years before France even started its pilot. Yet as of 2024, only an estimated 30,000 to 32,000 patients were receiving private prescriptions, against a backdrop of approximately 1.8 million people reportedly self-medicating with illegal cannabis.
The barriers are structural and cultural rather than legislative. NHS prescriptions remain exceedingly rare, kept off-limits by the absence of formal clinical guidance and the caution of NHS commissioners. That forces patients into private consultation models, consultation fees, prescription costs, and supply variability that effectively price out anyone without disposable income. A 2023 estimate put underground cannabis spending in the UK at £3.57 billion, much of it from people who cannot afford or navigate the legal private market.
France is not heading toward a UK-style outcome, the social security reimbursement framework, if enacted with meaningful coverage rates, will prevent that. But the UK comparison is a useful reminder that legal status and market access are entirely different things. A market can be technically open and practically inaccessible at the same time.
When Will French Patients Actually Be Able to Access Medical Cannabis Under the New Framework?
Based on the current timeline, realistically not before 2027.
If the decree is published in July, it then goes to the Conseil d’État for review. Assuming no major objections, HAS could deliver its formal reimbursement opinion in autumn 2026. Only after that can companies begin registering products with ANSM. Product registration, supply chain buildout, pharmacist training, and prescriber certification all take time.
The patients currently in the transitional phase, those who were enrolled in the pilot and have continued receiving treatment will be maintained under the existing framework until three months after HAS publishes its formal opinion. After that, they move to the new system. New patients cannot enter until that system is fully operational.
What Happens Next, and Why Does It Matter for Europe?
France is not just another national market. With its population of 68 million, universal healthcare system, and robust pharmaceutical infrastructure designed for drug standardization, France possesses all the elements to become one of Europe’s largest medical cannabis markets. If the country manages access barriers effectively, its total addressable population could even surpass Germany’s.
The companies, distributors, and healthcare systems paying attention right now are the ones that will be positioned when the framework clicks into place. The July publication is not a finish line. It is the starting gun for a process that will unfold over the next 12 to 18 months.
Patients with refractory neuropathic pain, palliative conditions, MS spasticity, and treatment-resistant epilepsy have been waiting since 2021 for a system that was only supposed to take two years to implement. July matters because it represents the first credible official commitment to a timeline. That matters less than the reimbursement decision that follows it. But it matters.
Frequently Asked Questions
France’s Minister of Health confirmed the publication of regulatory texts for the medical cannabis market by July 2026. However, prescribing cannot start immediately as the decree needs to clear several administrative hurdles, including a review by the Conseil d’État and a formal reimbursement opinion from HAS.
Realistically, prescriptions won’t be available until early 2027 at the earliest. First, the decree must be published. Then, the Conseil d’État needs to clear it, and HAS must provide a reimbursement opinion (expected in autumn 2026). Finally, ANSM will need to register the products.
U.CANNABIS was France’s official scientific evaluation of its medical cannabis pilot program. The study, commissioned by ANSM, tracked nearly 2,000 patients and found that medical cannabis use led to significant reductions in opioid, analgesic, and benzodiazepine consumption. These compelling results provided the evidence needed to push for a firm regulatory timeline from the French government.
Initially, no. French cultivators won’t be ready to meet demand until around 2028 due to ongoing GMP certification. For the first few years, France will rely on imports from countries like Canada, Portugal, and Denmark.
